Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance
Xiaoqing Cheng(Washington University in St. Louis), Ron Bose(Washington University in St. Louis)
Cited by 0
Related Papers
Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
|Molecular & Cellular Proteomics|2012|47
Breast Cancer Mutations <i>HER2V777L</i> and <i>PIK3CAH1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
|Cancer Research|2023|31
Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types
|Scientific Reports|2017|14
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0